[go: up one dir, main page]

TN2009000399A1 - Procedes de traitement impliquant l'inhibition de pi3k-alpha au moyen d'inhibiteurs de type quinaxoline - Google Patents

Procedes de traitement impliquant l'inhibition de pi3k-alpha au moyen d'inhibiteurs de type quinaxoline

Info

Publication number
TN2009000399A1
TN2009000399A1 TNP2009000399A TN2009000399A TN2009000399A1 TN 2009000399 A1 TN2009000399 A1 TN 2009000399A1 TN P2009000399 A TNP2009000399 A TN P2009000399A TN 2009000399 A TN2009000399 A TN 2009000399A TN 2009000399 A1 TN2009000399 A1 TN 2009000399A1
Authority
TN
Tunisia
Prior art keywords
quinaxolin
pi3k
alpha
treatment methods
methods involving
Prior art date
Application number
TNP2009000399A
Other languages
English (en)
Inventor
Peter Lamb
David Matthews
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of TN2009000399A1 publication Critical patent/TN2009000399A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des procédés de traitement du cancer impliquant l'administration d'un composé de formule I ou, éventuellement, d'un sel, solvate et/ou hydrate de celui-ci acceptable sur le plan pharmaceutique, en association avec d'autres traitements anticancéreux
TNP2009000399A 2007-04-11 2009-09-30 Procedes de traitement impliquant l'inhibition de pi3k-alpha au moyen d'inhibiteurs de type quinaxoline TN2009000399A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92316407P 2007-04-11 2007-04-11
PCT/US2008/004570 WO2008127594A2 (fr) 2007-04-11 2008-04-08 Procédés de traitement impliquant l'inhibition de pi3k-alpha au moyen d'inhibiteurs de type quinaxoline

Publications (1)

Publication Number Publication Date
TN2009000399A1 true TN2009000399A1 (fr) 2010-12-31

Family

ID=39864581

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000399A TN2009000399A1 (fr) 2007-04-11 2009-09-30 Procedes de traitement impliquant l'inhibition de pi3k-alpha au moyen d'inhibiteurs de type quinaxoline

Country Status (33)

Country Link
US (1) US8481001B2 (fr)
EP (1) EP2139483B9 (fr)
JP (2) JP5726515B2 (fr)
KR (1) KR101586774B1 (fr)
CN (2) CN103202842A (fr)
AU (1) AU2008239668B2 (fr)
BR (1) BRPI0810208A2 (fr)
CA (1) CA2684056A1 (fr)
CO (1) CO6140024A2 (fr)
CR (1) CR11099A (fr)
CY (1) CY1114608T1 (fr)
DK (1) DK2139483T3 (fr)
EA (1) EA019064B1 (fr)
EC (1) ECSP099723A (fr)
ES (1) ES2438998T3 (fr)
GT (1) GT200900263A (fr)
HR (1) HRP20131081T1 (fr)
IL (1) IL201211A (fr)
MA (1) MA31335B1 (fr)
ME (1) ME00937B (fr)
MX (1) MX2009010929A (fr)
MY (1) MY150797A (fr)
NI (1) NI200900184A (fr)
NZ (1) NZ580009A (fr)
PL (1) PL2139483T3 (fr)
PT (1) PT2139483E (fr)
RS (1) RS53020B (fr)
SI (1) SI2139483T1 (fr)
SV (1) SV2009003390A (fr)
TN (1) TN2009000399A1 (fr)
UA (1) UA98141C2 (fr)
WO (1) WO2008127594A2 (fr)
ZA (1) ZA200906765B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116188C2 (uk) * 2005-10-07 2018-02-26 Екселіксіс, Інк. Інгібітори фосфатидилінозит-3-кінази і способи їх застосування
US8044062B2 (en) * 2005-10-07 2011-10-25 Exelixis, Inc. Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha
CA2658725A1 (fr) 2006-08-16 2008-02-21 Exelixis, Inc. Procedes d'utilisation de modulateurs pi3k etmek
WO2008124161A1 (fr) * 2007-04-10 2008-10-16 Exelixis, Inc. Méthodes de traitement du cancer à l'aide d'inhibiteurs de pi3k alpha à base de pyridopyrimidinone
PL2374802T3 (pl) * 2008-11-10 2014-09-30 Kyowa Hakko Kirin Co Ltd Inhibitor wytwarzania kinureniny
DE102009049679A1 (de) 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
UY33221A (es) 2010-02-09 2011-09-30 Univ California MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
TW201244719A (en) 2010-07-09 2012-11-16 Exelixis Inc Combinations of kinase inhibitors for the treatment of cancer
CA2812089C (fr) 2010-09-14 2020-02-18 Exelixis Inc. Inhibiteurs de pi3k-delta et leurs procedes d'utilisation et fabrication
EA201390582A1 (ru) 2010-10-20 2013-09-30 Мерк Сероно С.А. Женева Способ получения замещенных n-(3-аминохиноксалин-2-ил)сульфонамидов и их промежуточных n-(3-хлорхиноксалин-2-ил)сульфонамидов
DE102010048800A1 (de) 2010-10-20 2012-05-10 Merck Patent Gmbh Chinoxalinderivate
DE102010049595A1 (de) 2010-10-26 2012-04-26 Merck Patent Gmbh Chinazolinderivate
WO2012065057A2 (fr) 2010-11-12 2012-05-18 Exelixis, Inc. Inhibiteurs de la phosphatidylinositol 3-kinase et leurs procédés d'utilisation
BR112014005858A2 (pt) * 2011-09-14 2017-06-13 Exelixis Inc inibidores de fosfatidilinositol 3-quinase para tratamento de câncer
CA2850763A1 (fr) * 2011-10-04 2013-04-11 Gilead Calistoga Llc Nouveaux inhibiteurs de quinoxaline de la voie pi3k
WO2013056067A1 (fr) 2011-10-13 2013-04-18 Exelixis, Inc. Composés pour une utilisation dans le traitement de carcinome des cellules basales
PH12014500897A1 (en) * 2011-10-28 2019-10-07 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013067141A1 (fr) * 2011-11-01 2013-05-10 Exelixis, Inc. N-(3-{[(3-{[2-chloro-5-(méthoxy)phényl]amino}quinoxalin-2-yl)amino]sulfonyl}phényl)-2-méthylalaninamide en tant qu'inhibiteur de la phosphatidylinositol-3-kinase pour le traitement de malignités lymphoprolifératives
WO2013067306A1 (fr) * 2011-11-02 2013-05-10 Exelixis, Inc. Inhibiteurs de la phosphatidylinositol 3-kinase pour le traitement de cancers chez les enfants
WO2013101964A1 (fr) * 2011-12-27 2013-07-04 Kadmon Corporation, Llc Procédés de traitement d'un cancer du sein ne répondant pas au trastuzumab
US9499561B2 (en) 2012-04-10 2016-11-22 Shanghai Yingli Pharmaceutical Co., Ltd. Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof
US9487526B2 (en) 2012-08-13 2016-11-08 Takeda Pharmaceutical Company Limited Quinoxaline derivatives as GPR6 modulators
JP6441910B2 (ja) 2013-09-30 2018-12-19 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合ピリミジン化合物、中間体、その調製方法、組成物及び使用
CN106831722B (zh) 2013-10-16 2019-08-30 上海璎黎药业有限公司 稠合杂环化合物、其制备方法、药物组合物和用途
US10179783B2 (en) 2014-02-14 2019-01-15 Taketa Pharmaceutical Company Limited Tetrahydropyridopyrazines as modulators of GPR6
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
WO2019119206A1 (fr) * 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Inhibiteurs puriques de la phosphatidylinositol 3-kinase delta humaine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1599196A4 (fr) * 2003-01-17 2006-05-31 Threshold Pharmaceuticals Inc Polytherapies anticancereuses
WO2007023186A1 (fr) * 2005-08-26 2007-03-01 Laboratoires Serono S.A. Derive de pyrazine et leur utilisation en tant qu'inhibiteurs de pi3k
US8044062B2 (en) * 2005-10-07 2011-10-25 Exelixis, Inc. Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha
UA116188C2 (uk) * 2005-10-07 2018-02-26 Екселіксіс, Інк. Інгібітори фосфатидилінозит-3-кінази і способи їх застосування
CA2658725A1 (fr) * 2006-08-16 2008-02-21 Exelixis, Inc. Procedes d'utilisation de modulateurs pi3k etmek
MX2009009031A (es) 2007-02-22 2009-08-31 Merck Serono Sa Compuestos de quinoxalina y uso de los mismos.
WO2008124161A1 (fr) * 2007-04-10 2008-10-16 Exelixis, Inc. Méthodes de traitement du cancer à l'aide d'inhibiteurs de pi3k alpha à base de pyridopyrimidinone
JP4623164B2 (ja) * 2008-08-21 2011-02-02 セイコーエプソン株式会社 プロジェクタ

Also Published As

Publication number Publication date
US20110123434A1 (en) 2011-05-26
HRP20131081T1 (hr) 2013-12-20
EP2139483B1 (fr) 2013-09-18
MY150797A (en) 2014-02-28
CN103202842A (zh) 2013-07-17
PT2139483E (pt) 2013-12-27
SI2139483T1 (sl) 2013-11-29
IL201211A0 (en) 2010-05-31
SV2009003390A (es) 2010-05-21
GT200900263A (es) 2014-01-15
KR20100019436A (ko) 2010-02-18
MX2009010929A (es) 2010-01-20
KR101586774B1 (ko) 2016-01-19
EA019064B1 (ru) 2013-12-30
AU2008239668B2 (en) 2013-11-07
HK1140141A1 (en) 2010-10-08
NZ580009A (en) 2012-06-29
EA200970935A1 (ru) 2010-04-30
ECSP099723A (es) 2010-03-31
JP5726515B2 (ja) 2015-06-03
US8481001B2 (en) 2013-07-09
CN101959516B (zh) 2013-05-08
WO2008127594A3 (fr) 2009-04-30
ZA200906765B (en) 2010-05-26
IL201211A (en) 2015-09-24
NI200900184A (es) 2011-09-08
EP2139483A2 (fr) 2010-01-06
RS53020B (sr) 2014-04-30
DK2139483T3 (da) 2014-01-13
JP2010523669A (ja) 2010-07-15
CO6140024A2 (es) 2010-03-19
JP2014074031A (ja) 2014-04-24
EP2139483B9 (fr) 2014-05-21
CR11099A (es) 2010-01-19
PL2139483T3 (pl) 2014-02-28
BRPI0810208A2 (pt) 2014-10-21
UA98141C2 (ru) 2012-04-25
ME00937B (fr) 2012-06-20
MA31335B1 (fr) 2010-04-01
WO2008127594A2 (fr) 2008-10-23
CY1114608T1 (el) 2016-10-05
CN101959516A (zh) 2011-01-26
ES2438998T3 (es) 2014-01-21
AU2008239668A1 (en) 2008-10-23
CA2684056A1 (fr) 2008-10-23

Similar Documents

Publication Publication Date Title
TN2009000399A1 (fr) Procedes de traitement impliquant l'inhibition de pi3k-alpha au moyen d'inhibiteurs de type quinaxoline
MA31358B1 (fr) Méthodes de traitement du cancer à l'aide d'inhibiteurs de pi3k alpha à base de pyridopyrimidinone
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
MA34207B1 (fr) Inhibiteurs de la pi3 kinase et/ou du mtor
SG179418A1 (en) Inhibitors of the hedgehog pathway
MA32903B1 (fr) Inhibiteurs de proteine-kinases
ATE534377T1 (de) Verfahren und zusammensetzungen zur behandlung von hämatologischen erkrankungen
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
MA33076B1 (fr) Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer
TN2009000444A1 (en) Combination therapy with a compound acting as a plateletadp receptor inhibitor
ATE537175T1 (de) Neue piperazino-dihydrothienopyrimidin-derivate
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
IL192100A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
MA38315A1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
UA104148C2 (ru) [4-(5-аминометил-2-фторфенил)-пиперидин-1-ил]-[7-фтор-1-(2-метоксиэтил)-4-трифторметокси-1h-индол-3-ил]-метанон как ингибитор триптазы тучных клеток
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
MA34547B1 (fr) Traitement d'association pour traiter une infection par le vhc
MA35347B1 (fr) Procedes therapeuiques
TW200602035A (en) [4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase
MY156278A (en) Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones
NO20070250L (no) S-Tenatoprazol-natriummonohydratsalt og dennes anvendelse i form av en protonpumpe-inhibitor
UA99612C2 (en) Inhibitors of the hedgehog pathway